Applied
UV and
3Sixty Biopharmaceuticals
Sign
Exclusive
Distribution
Agreement for
Airocide®
Air Purification Systems for
the
Continent of Africa
$3.5
million
minimum
first
year
purchase commitment
of
Airocide®
systems
Mount Vernon, NY
// May 19, 2021 -- InvestorsHub
NewsWire -- Applied UV, Inc. (NasdaqCM: AUVI) ("Applied UV" or the "Company"), an
infection control technology company that applies the power of
narrow-range ultraviolet light ("UVC") for surface areas and
catalytic bioconversion technology for air purification to destroy
pathogens safely, thoroughly, and automatically,
today
announced
the
signing of an exclusive
distribution
agreement
with 3Sixty Biopharmaceuticals
(Pty) Ltd. ("3Sixty")
for
the distribution of the Airocide®
consumer and commercial air purification systems
within
the
continent
of
Africa.
3Sixty
is one of the largest black
owned companies
in
South Africa with
a primary
focus
on the market that addresses
the
healthcare crisis due to the global pandemic.
Under the terms of the agreement, 3Sixty
has agreed to an upfront
binding purchase
commitment of a minimum of $3.5 million of
Airocide®
systems over the initial one-year term of the
agreement.
After
the
initial term, both
parties have
agreed
to assess
opportunities to
expand
the
product line to include the
SteriLumen
platform
of connected
UVC
devices
for
infection control in and around high-traffic areas.
Commenting
on the agreement,
Khandani
Msibi,
Group
CEO
of 3Sixty Global
Solutions Group said,
"We
are extremely pleased to partner with SteriLumen and appreciate the
trust they have placed in 3Sixty
and our dedicated
clinical
solutions team.
Air
and surface infection
control is a serious safety issue for the public, and offering
the Airocide®
systems will
provide additional choice for our customers. SteriLumen shares our
commitment to innovation and high-quality products that help
protect people's lives.
We look forward to this new addition to our best-in-class
portfolio, as well as leveraging our geographic reach, sales,
service, and technical capabilities, helping accelerate and grow
our businesses together."
"3Sixty
is a great partner for the Airocide
brand.
They have the scale, infrastructure, reputation,
and experience
to make the
Airocide® system a
market leader in Africa.
We are pleased that 3Sixty recognized the quality,
innovation,
performance and safety
of our Airocide®
system",
said Q Saeed, CEO of Applied UV.
Airocide® System
The Airocide™ System, originally developed by NASA with assistance
from the University of Wisconsin at Madison,
is an airborne pathogen killing technology that uses a patented
combination of UVC and a proprietary, titanium dioxide based
photocatalyst. Listed as an FDA Class II Medical device, the
Airocide™ technology is clinically proven and field tested to
kill/remove/eliminate airborne pathogenic and non-pathogenic
microorganisms, allergens, odors and harmful VOCs in a variety of
applications and industries including healthcare, hospitality,
grocery chains, wineries, commercial real estate, schools, dental
offices and homes. Airocide® air purifiers are available
at www.airocide.com.
About
3Sixty Biopharmaceuticals
(Pty) Ltd.
3Sixty
Biopharmaceuticals (Pty) Ltd is a South African company based in
Johannesburg, the commercial hub of South Africa.
The
company is committed to the development and
commercialization
of South African intellectual property and it seeks to achieve this
either by itself or through collaboration with principals both from
the private and/or public sector.
About
Applied UV
Applied
UV is focused on the development and acquisition of technology that
address infection
control
in the
healthcare, hospitality, commercial and municipal
markets.
The Company has two wholly owned subsidiaries -
SteriLumen,
Inc. ("SteriLumen") and Munn Works, LLC ("Munn Works").
SteriLumen's
connected platform for Data Driven Disinfection™
applies
the power of ultraviolet
light (UVC) to
destroy pathogens safely, thoroughly, and
automatically,
addressing the challenge of healthcare-acquired
infections ("HAIs").
Targeted
for use in facilities that have high customer turnover such as
hospitals, hotels,
commercial facilities,
and other public spaces,
the
Company's Lumicide™
platform
uses UVC LEDs
in
several patented designs
for
infection
control
in
and around
high-traffic areas,
including sinks and restrooms,
killing bacteria,
viruses,
and other pathogens residing on hard surfaces
within
devices'
proximity.
The Company's patented in-drain disinfection
device,
Lumicide Drain,
is the only product
on the market
that addresses this critical pathogen intensive location.
SteriLumen's Airocide® products for air purification,
developed by NASA and FDA Cleared as class II medical devices,
utilize a proprietary photo-catalytic bioconversion technology that
draws air into a reaction chamber that converts damaging molds,
microorganisms, dangerous pathogens, destructive VOCs and
biological gasses into harmless water vapor without producing ozone
or other harmful byproducts. Airocide®
applications include healthcare, hospitality, grocery chains, wine
making facilities, commercial real estate, schools, dental
offices,
and homes.
For more
information about Applied UV, Inc., and its subsidiaries, please
visit the following websites:
https://www.applieduvinc.com/;
https://sterilumen.com/; and,
https://munnworks.com/.
Forward-Looking
Statements
The information
contained herein may contain "forward-looking statements."
Forward-looking statements reflect the current view about future
events. When used in this press release, the words "anticipate,"
"believe," "estimate," "expect," "future," "intend," "plan," or the
negative of these terms and similar expressions, as they relate to
us or our management, identify forward-looking statements. Such
statements include, but are not limited to, statements contained in
this press release relating to the view of management of Applied UV
concerning its business strategy, future operating results and
liquidity and capital resources outlook. Forward-looking statements
are based on the Company's current expectations and assumptions
regarding its business, the economy and other future conditions.
Because forward-looking statements relate to the future, they are
subject to inherent uncertainties, risks and changes in
circumstances that are difficult to predict. The Company's actual
results may differ materially from those contemplated by the
forward-looking statements. They are neither statements of
historical fact nor guarantees of assurance of future performance.
We caution you therefore against relying on any of these
forward-looking statements. Factors or events that could cause the
Company's actual results to differ may emerge from time to time,
and it is not possible for the Company to predict all of them. The
Company cannot guarantee future results, levels of activity,
performance, or achievements. Except as required by applicable law,
including the securities laws of the United States, the Company
does not intend to update any of the forward-looking statements to
conform these statements to actual results.
Applied UV
Investor Relations
TraDigital IR
Kevin
McGrath
TraDigital IR
+1-646-418-7002
kevin@tradigitalir.com